Back to News
Market Impact: 0.12
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Source: globenewswire.com
Capital Returns (Dividends / Buybacks)Company Fundamentals
Zealand Pharma (Nasdaq: ZEAL) issued a correction related to its share buy-back program, covering transactions for week 35 of 2026. The announcement is administrative and does not indicate a change in the underlying buyback pace or broader operating outlook. Net impact on the stock is likely limited.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Alibaba shares jump as new AI chip, data center buildout plans unveiled
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- The show must go on: struggling luxury brands seek catwalk boost in Milan and Paris
- Serabi reports first-half profit of $30.1 million
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework